Clinical Trials Directory

Trials / Unknown

UnknownNCT03982862

Botulinum Toxins Intralesional Injection for Scar Pain

Intralesional Injection of Steroids and/or Botulinum Toxin Type A in Hypertrophic Scars and Keloids for Pain Improvement

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
Kaohsiung Medical University · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Botulinum toxins has been approved by the FDA to treat chronic migraine. Botox had been shown to inhibiting the release of inflammatory mediators and peripheral neurotransmitters from sensory nerve to treat neuropathic pain. In the clinical practice, botox indeed effect in scar pain. However, investigators need well controlled study to prove this finding and assess the improvement of scar appearance.

Detailed description

After surgery or trauma, scar tissues would form during the healing process. However, hypertrophic scars and keloids might happen to some patients, both of which are often pruritic and erythematous. Besides, the markedly elevated tumor-like appearance usually brings much concern to patients. Moreover, significant pain or discomfort could happen to keloids. Various treatment strategies were mentioned but without a solid solution to all of the scars. Investigators hope to evaluate the differences of scar volume, appearance and symptoms (itching and pain) in participants receiving simultaneous intralesional injection of Botulinum toxin type A and/or steroids. Besides, side effects would also be recorded. Investigators hope to establish a more effective intralesional injection therapy for participatns suffering from hypertrophic scars and keloids.

Conditions

Interventions

TypeNameDescription
DRUGTriamcinoloneTriamcinolone 4mg diluted to 0.1 ml
DRUGLidocaine0.1ml 2% Xylocaine
DRUGBotulinum toxin A4U Botox® diluted to 0.1 ml

Timeline

Start date
2018-07-30
Primary completion
2019-06-30
Completion
2019-06-30
First posted
2019-06-12
Last updated
2019-06-17

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT03982862. Inclusion in this directory is not an endorsement.